MYGN - Myriad Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
29.67
+1.45 (+5.14%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close28.62
Open28.72
Bid27.75 x 800
Ask30.40 x 1300
Day's Range28.72 - 29.71
52 Week Range26.80 - 50.44
Volume467,310
Avg. Volume1,047,751
Market Cap2.218B
Beta (3Y Monthly)1.42
PE Ratio (TTM)41.91
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now
    Zacks3 days ago

    Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now

    On the success of the Elevate 2020 program, along with augmenting reimbursements for tests, Myriad Genetics (MYGN) seems to be well-positioned to deliver strong financial results in fiscal 2019.

  • Markit6 days ago

    See what the IHS Markit Score report has to say about Myriad Genetics Inc.

    # Myriad Genetics Inc ### NASDAQ/NGS:MYGN View full report here! ## Summary * Bearish sentiment is moderate ## Bearish sentiment Short interest | Negative Short interest is moderately high for MYGN with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $2.90 billion over the last one-month into ETFs that hold MYGN are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • MYGN vs. SWTUY: Which Stock Should Value Investors Buy Now?
    Zacks10 days ago

    MYGN vs. SWTUY: Which Stock Should Value Investors Buy Now?

    MYGN vs. SWTUY: Which Stock Is the Better Value Option?

  • Has Myriad Genetics (MYGN) Outpaced Other Medical Stocks This Year?
    Zacks10 days ago

    Has Myriad Genetics (MYGN) Outpaced Other Medical Stocks This Year?

    Is (MYGN) Outperforming Other Medical Stocks This Year?

  • Markit12 days ago

    See what the IHS Markit Score report has to say about Myriad Genetics Inc.

    # Myriad Genetics Inc ### NASDAQ/NGS:MYGN View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate ## Bearish sentiment Short interest | Negative Short interest is moderately high for MYGN with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding MYGN are favorable, with net inflows of $5.58 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Epizyme to File NDA for Tazemetostat in Follicular Lymphoma
    Zacks13 days ago

    Epizyme to File NDA for Tazemetostat in Follicular Lymphoma

    Epizyme (EPZM) announces that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma.

  • Aerie's Rhopressa Succeeds in Study on Japanese Patients
    Zacks13 days ago

    Aerie's Rhopressa Succeeds in Study on Japanese Patients

    Aerie (AERI) announces encouraging top-line results from its pilot phase II study of netarsudil ophthalmic solution in a Japan.

  • Why the Earnings Surprise Streak Could Continue for Myriad (MYGN)
    Zacks14 days ago

    Why the Earnings Surprise Streak Could Continue for Myriad (MYGN)

    Myriad (MYGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Myriad Genetics (MYGN) Catches Eye: Stock Jumps 6.9%
    Zacks14 days ago

    Myriad Genetics (MYGN) Catches Eye: Stock Jumps 6.9%

    Myriad Genetics (MYGN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • Jazz Inks Deal with Codiak to Develop Exosome Therapeutics
    Zacks16 days ago

    Jazz Inks Deal with Codiak to Develop Exosome Therapeutics

    Jazz (JAZZ) collaborates with Codiak for research, development and commercialization of exosome therapeutics to treat cancer.

  • Novo Nordisk Boasts Strong Diabetes Presence and Pipeline
    Zacks18 days ago

    Novo Nordisk Boasts Strong Diabetes Presence and Pipeline

    Novo Nordisk (NVO) has a strong presence in the Diabetes Care market and boasts a strong pipeline, with focus on therapeutic proteins within insulin.

  • Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply
    Zacks18 days ago

    Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply

    Sarepta (SRPT) inks long-term strategic deal with Aldevron for the supply of plasmid DNA to fulfill the former's needs for its gene-therapy clinical trials and commercial supply.

  • The Wall Street Journal22 days ago

    [$$] Peter Meldrum Helped Found Myriad Genetics to Find Genes Linked to Inherited Cancers

    Peter Meldrum had run an agricultural biotechnology company and advised scores of startups by the time he met Mark Skolnick in 1991. Dr. Skolnick, a geneticist at the University of Utah, was in a race with other scientists to find genes responsible for inherited forms of breast and other cancers. Mr. Meldrum quickly agreed to join Dr. Skolnick in founding Myriad Genetics in Salt Lake City in 1992.

  • Horizon Pharma's Ravicti Gets FDA Nod for Expanded Age Group
    Zacks24 days ago

    Horizon Pharma's Ravicti Gets FDA Nod for Expanded Age Group

    Horizon Pharma's Ravicti Oral Liquid gets FDA approval to expand the age range to include infants younger than two months, living with a urea cycle disorder.

  • Myriad Genetics Posts Positive Adjusted Vectra Test Data
    Zacks25 days ago

    Myriad Genetics Posts Positive Adjusted Vectra Test Data

    The key finding of Myriad Genetics' (MYGN) study proves that the adjusted Vectra score beats all traditional measures of disease activity to predict radiographic progression in RA patients.

  • AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions
    Zacks25 days ago

    AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions

    AMAG's (AMAG) share improve 9.7% year to date courtesy of label expansion efforts as well as acquisitions and deals.

  • U.S. Political Tumult Shrouds Markets: 5 Safe Picks
    Zacks26 days ago

    U.S. Political Tumult Shrouds Markets: 5 Safe Picks

    Trump's continuous bashing of the Fed and Treasury Secretary Steven Mnuchin's phone calls to major banks to assess their financial health have been unnerving investors.

  • Should Myriad Genetics, Inc. (NASDAQ:MYGN) Focus On Improving This Fundamental Metric?
    Simply Wall St.27 days ago

    Should Myriad Genetics, Inc. (NASDAQ:MYGN) Focus On Improving This Fundamental Metric?

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...

  • See what the IHS Markit Score report has to say about Myriad Genetics Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Myriad Genetics Inc.

    Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • 6 Genome Sequencing Stocks to Buy for Big Health-Care Profits
    Kiplingerlast month

    6 Genome Sequencing Stocks to Buy for Big Health-Care Profits

    Genome sequencing - basically figuring out the order of DNA, the building blocks of life - was once essentially little more than a lab exercise. But now, it has reached commercial viability and then some. The field of genomics goes back to the 1950s, though it really started in earnest with the start of the Human Genome Project in 1990 - a 13-year, $2.7 billion enterprise that was completed in April 2013. Genome sequencing, in which scientists and their myriad machines detail the entire set of human DNA, has fantastic medical potential, allowing researchers to find genetic mutations - errors that can be harmless at times, but other times debilitating or even fatal. Moreover, genome sequencing is starting to reach realistic pricing - the costs have fallen down to about $1,000 at the low end, and companies are racing to cash in on the myriad opportunities. Here are six genome sequencing stocks to buy for this emerging medical technology. While genomics isn't the biggest investing buzzword today, this is a promising niche of the market that could take off as it gains more prominence. SEE ALSO: 19 Best Retirement Stocks to Buy in 2019

  • Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base
    Zackslast month

    Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base

    Myriad Genetics (MYGN) progresses well with initiatives to boost the uptake of the BRACAnalysis CDx test. The recent approval to increase the customer base is an added positive.

  • Myriad Genetics, Inc. (MYGN): Are Hedge Funds Right About This Stock?
    Insider Monkeylast month

    Myriad Genetics, Inc. (MYGN): Are Hedge Funds Right About This Stock?

    Is Myriad Genetics, Inc. (NASDAQ:MYGN) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more resources than the average investor. The funds have access […]

  • Zackslast month

    Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now

    Myriad Genetics (MYGN) see strong testing volumes from new products.

  • Here's Why Myriad Genetics Lost 28.4% in November
    Motley Foollast month

    Here's Why Myriad Genetics Lost 28.4% in November

    The genetic testing pioneer announced fiscal first-quarter 2019 results, but had to reduce full-year revenue guidance.

  • Zackslast month

    Myriad Genetics Announces Encouraging EndoPredict Test Data

    Myriad Genetics (MYGN) forges ahead with initiatives to boost the adoption of the EndoPredict tests.